Interleukin-6, infection and cardiovascular outcomes in acute heart failure : Findings from the EDIFICA registry
Copyright © 2022 Elsevier Ltd. All rights reserved..
AIMS: Interleukin-6 (IL-6) is upregulated in response to infectious and inflammatory triggers and independently predicts all-cause mortality in acute heart failure (AHF). However, the association of IL-6 with cardiovascular outcomes and its interplay with C-reactive protein and infection, a major precipitating factor in AHF, remains poorly understood.
METHODS AND RESULTS: The association between IL-6 and clinical outcomes (180 days) in AHF was evaluated using a cohort of 164 patients from the EDIFICA registry. Median IL-6 levels at admission were 17.4 pg/mL. Patients in the higher admission IL-6 tertile presented with lower blood pressure and more congestion, were diagnosed more frequently with infection, and had a longer hospital stay. Higher IL-6 levels were associated with increased risk of HF rehospitalization (hazard ratio per log2 3.69, 95% confidence interval (CI) 1.26-10.8, p =.017) and the composite of HF rehospitalization or cardiovascular death (hazard ratio per log2 3.50; 95% CI 1.28-9.57; p =.014), independently of major AHF prognosticators, including B-type natriuretic peptide and renal function. However, no independent associations were found for all-cause rehospitalization or mortality. Despite a moderate correlation of IL-6 with C-reactive protein (CRP) levels (R = .51), the latter were not associated with clinical outcomes in this population.
CONCLUSIONS: IL-6 levels associate with higher rate of cardiovascular events in AHF, independently of classical prognosticators and evidence of infection, outperforming CRP as an inflammatory outcome biomarker.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:160 |
|---|---|
| Enthalten in: |
Cytokine - 160(2022) vom: 15. Dez., Seite 156053 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vasques-Nóvoa, Francisco [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.10.2022 Date Revised 22.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cyto.2022.156053 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346950473 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346950473 | ||
| 003 | DE-627 | ||
| 005 | 20231226032654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cyto.2022.156053 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM346950473 | ||
| 035 | |a (NLM)36179534 | ||
| 035 | |a (PII)S1043-4666(22)00262-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vasques-Nóvoa, Francisco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interleukin-6, infection and cardiovascular outcomes in acute heart failure |b Findings from the EDIFICA registry |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.10.2022 | ||
| 500 | |a Date Revised 22.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a AIMS: Interleukin-6 (IL-6) is upregulated in response to infectious and inflammatory triggers and independently predicts all-cause mortality in acute heart failure (AHF). However, the association of IL-6 with cardiovascular outcomes and its interplay with C-reactive protein and infection, a major precipitating factor in AHF, remains poorly understood | ||
| 520 | |a METHODS AND RESULTS: The association between IL-6 and clinical outcomes (180 days) in AHF was evaluated using a cohort of 164 patients from the EDIFICA registry. Median IL-6 levels at admission were 17.4 pg/mL. Patients in the higher admission IL-6 tertile presented with lower blood pressure and more congestion, were diagnosed more frequently with infection, and had a longer hospital stay. Higher IL-6 levels were associated with increased risk of HF rehospitalization (hazard ratio per log2 3.69, 95% confidence interval (CI) 1.26-10.8, p =.017) and the composite of HF rehospitalization or cardiovascular death (hazard ratio per log2 3.50; 95% CI 1.28-9.57; p =.014), independently of major AHF prognosticators, including B-type natriuretic peptide and renal function. However, no independent associations were found for all-cause rehospitalization or mortality. Despite a moderate correlation of IL-6 with C-reactive protein (CRP) levels (R = .51), the latter were not associated with clinical outcomes in this population | ||
| 520 | |a CONCLUSIONS: IL-6 levels associate with higher rate of cardiovascular events in AHF, independently of classical prognosticators and evidence of infection, outperforming CRP as an inflammatory outcome biomarker | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Acute heart failure | |
| 650 | 4 | |a Infection | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Interleukin-6 | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a IL6 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Pedro Ferreira, João |e verfasserin |4 aut | |
| 700 | 1 | |a Marques, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Sergio Neves, João |e verfasserin |4 aut | |
| 700 | 1 | |a Vale, Catarina |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeirinho-Soares, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Marques, José |e verfasserin |4 aut | |
| 700 | 1 | |a Martins, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Tiago Guimarães, João |e verfasserin |4 aut | |
| 700 | 1 | |a Barros, António S |e verfasserin |4 aut | |
| 700 | 1 | |a Leite-Moreira, Adelino F |e verfasserin |4 aut | |
| 700 | 1 | |a Roncon-Albuquerque, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Almeida, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Bettencourt, Paulo |e verfasserin |4 aut | |
| 700 | 1 | |a Friões, Fernando |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytokine |d 1994 |g 160(2022) vom: 15. Dez., Seite 156053 |w (DE-627)NLM012645575 |x 1096-0023 |7 nnns |
| 773 | 1 | 8 | |g volume:160 |g year:2022 |g day:15 |g month:12 |g pages:156053 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cyto.2022.156053 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 160 |j 2022 |b 15 |c 12 |h 156053 | ||